Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. The vaccines were safe but interferon-γ ELISPOT responses were low compared to other poxvirus vectors, despite targeting multiple antigens. There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene.

Original publication

DOI

10.1016/j.vaccine.2011.03.083

Type

Journal article

Journal

Vaccine

Publication Date

06/10/2011

Volume

29

Pages

7514 - 7522

Keywords

Adolescent, Adult, Antibodies, Protozoan, Antigens, Protozoan, Humans, Immunization, Secondary, Interferon-gamma, Malaria Vaccines, Malaria, Falciparum, Middle Aged, Plasmodium falciparum, Polyproteins, Protozoan Proteins, Treatment Outcome, Vaccination, Vaccines, Subunit, Young Adult